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ABSTRACT
Background: Currently, there is a lack of clarity in the literature as
to whether there is a definitive difference between the effects of
vitamins D2 and D3 in the raising of serum 25-hydroxyvitamin D
[25(OH)D].
Objective: The objective of this article was to report a systematic
review and meta-analysis of randomized controlled trials (RCTs)
that have directly compared the effects of vitamin D2 and vitamin
D3 on serum 25(OH)D concentrations in humans.
Design: The ISI Web of Knowledge (January 1966 to July 2011)
database was searched electronically for all relevant studies in adults
that directly compared vitamin D3 with vitamin D2. The Cochrane
Clinical Trials Registry, International Standard Randomized Con-
trolled Trials Number register, and clinicaltrials.gov were also
searched for any unpublished trials.
Results: A meta-analysis of RCTs indicated that supplementation
with vitamin D3 had a significant and positive effect in the raising of
serum 25(OH)D concentrations compared with the effect of vitamin
D2 (P = 0.001). When the frequency of dosage administration was
compared, there was a significant response for vitamin D3 when
given as a bolus dose (P = 0.0002) compared with administration
of vitamin D2, but the effect was lost with daily supplementation.
Conclusions: This meta-analysis indicates that vitamin D3 is more
efficacious at raising serum 25(OH)D concentrations than is vitamin
D2, and thus vitamin D3 could potentially become the preferred
choice for supplementation. However, additional research is required
to examine the metabolic pathways involved in oral and intramuscu-
lar administration of vitamin D and the effects across age, sex, and
ethnicity, which this review was unable to verify. Am J Clin Nutr
2012;95:1357–64.
INTRODUCTION
Compared with the other known vitamins essential to health,
vitamin D is unique in its role because of the diverse sources
available. Ergocalciferol (vitamin D2) is sourced from the UV
irradiation of ergosterol, which is a steroid found in some plants
but largely in fungi (1). Cholecalciferol (vitamin D3) is synthe-
sized via the UV irradiation of 7-dehydrocholesterol to previtamin
D3 in the skin of animals at UVB wavelengths of 290–320 nm,
with a further thermal isomerization step to form vitamin D3 (1, 2).
Therefore, humans have a combination of vitamins D2 and D3
available to them as part of a typical lifestyle from ambient UV
exposure (vitamin D3), habitual dietary intakes of vitamin D3–rich
foods (egg yolks and oily fish), fortified foods (margarine and
breakfast cereals, which generally have vitamin D2 fortification), and
vitamin supplements (both vitamins D2 and D3 are available) (2).
Vitamins D2 and D3 function as prohormones (which, there-
fore, have no biological effect), with the only differentiation
between the two being the structure of their side chains, and
thus, theoretically are used by the body in an identical manner
(2). The conversion of vitamins D2 and D3 into active com-
pounds (irrespective of source) requires a 2-step enzymatic
hydroxylation process to occur (2). At the first site, the liver,
vitamins D2 and D3 are converted to 25-hydroxyvitamin D
[25(OH)D]4 via the action of 25-hydroxylases (ie, microsomal
cytochrome P450 2R1 and mitochondrial cytochrome P450
27A1), which are known to be from the cytochrome P450 group
(2, 3). The kidney is the second site of activity where 1a-hydroxylase
(cytochrome P450 27B1) converts 25(OH)D to 1,25-dihydroxy-
vitamin D2 or D3 (calcitriol) (1, 2). However the rate of con-
version is under homeostatic control because of its dependence
on circulating parathyroid hormone concentrations (1). Once
calcitriol is available, the known systemic effects center on the
maintenance of serum calcium and phosphate concentrations via
the control of intestinal absorption of calcium, renal resorption
of phosphate, and the release of calcium from the skeleton (1).
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Although vitamins D2 and D3 have previously been described as
undertaking identical hydroxylation processes, which, thus, result
in the same active metabolite (calcitriol), data have arisen to show
that, in comparison, there may be a difference in their respective
efficacies in the raising of serum 25(OH)D (4–7), which is the
established marker of vitamin D status (1). Data suggested that
these proposed differences between the 2 calciferols are due to
their differing affinities for the vitamin D receptor (VDR), which
appears to be linked to an additional step of 24-hydroxylation that
inactivates calcitriol (8). In addition, it is thought that vitamin D3 is
potentially the preferred substrate for hepatic 25-hydroxylase (9),
which in combination with the possible difference in the 24-
hydroxylation rate, only reinforces the importance of determining
whether these metabolic anomalies impact on health.
Given the essential role vitamin D plays in maintaining bone
health and the gathering proof of widespread deficiency within
the UK population (10), it is essential that the most efficacious
source of vitamin D is elucidated. Therefore, the aim of this
systematic review and meta-analysis was to determine whether
there is a difference in the efficacy of vitamin D2 compared with
vitamin D3 in the raising of the serum 25(OH)D status within the
context of randomized controlled trials (RCTs).
METHODS
Identification of studies and quality assessment
A systematic search of the current literature was completed via
the use of the ISI Web of Knowledge (including MEDLINE and
Web of Science databases, http://wok.mimas.ac.uk/) and the
Cochrane Central Register of Controlled Trials (http://online
library.wiley.com/o/cochrane/cochrane_clcentral_articles_fs.html),
and the International Standard Randomized Controlled Trials
Number Register (www.isrctn.org) and clinicaltrials.gov databases
were also searched for any unpublished trials; the search covered
from January 1950 to November 2011. Search terms used were as
follows: “vitamin D2 and D3” or “ergocalciferol and cholecalcif-
erol” and “supplementation” and “25 hydroxyvitamin D.”
Two authors (HL and LT) screened article titles and abstracts
to identify studies that may be suitable for analysis. Full articles
were independently assessed (by HL, SL-N, and LT) for final
inclusion by using a scoring system for assessing quality (11). All
authors agreed on the final decision of the studies to be included.
Study eligibility criteria
Any randomized intervention trials that involved human adults
(men and women) that directly compared the effects of vitamin
D2 and vitamin D3 supplementation and used serum 25(OH)D
concentrations as a primary outcome were initially included for
consideration.
In addition to healthy participants, studies that had participants
with acute or chronicmedical conditions associatedwith vitaminD
insufficiency or poor musculoskeletal health were also included for
the initial review of articles. No studies were included that involved
children, adolescents, or pregnant or breastfeeding women. Var-
iations between the extracted studies for supplement dosage,
frequency of supplementation, use of either intramuscular or oral
delivery methods, and lack of a control or placebo group were
acceptable and were not cause for exclusion.
Data collection
All relevant information was extracted from eligible studies as
follows: first author, publication year, country of origin, study
design, supplement dosage, frequency of supplementation, method
of delivery (intramuscular compared with oral), serum 25(OH)D
concentrations, and demographic characteristics of the study
population. Any other information pertinent to the review such as
potential confounders to the RCTs (ie, the season during which
the RCT took place and risk of ambient UV exposure), the lack
of a control group, the analysis technique chosen to assess serum
25(OH)D, and the dropout rate were also noted when reported.
For all studies, the mean, SD (or equivalent), and n for ab-
solute change of serum 25(OH)D from baseline in addition to
baseline and postintervention measurements of serum 25(OH)D
were recorded. Depending on the author, data for serum 25(OH)D
concentrations were extracted as both nanograms per milliliter
and nanomoles per liter, with results converted to the SI unit of
nanomoles per liter for this review. If results were obtained as
SEMs, then they were converted to SDs by using the formula
SEM ¼ SD4 ﬃﬃﬃnp ð1Þ
Six articles had data missing that were required for review.
Five authors were contacted; current contact details were not
available for the sixth author (12). Of the authors contacted, 2
authors did not respond to the request for additional data (13, 14);
thus, these 2 studies were not included in the meta-analysis but
were still reviewed on a qualitative basis. Three authors responded
and were able to provide the necessary information (15–17) and
were subsequently included in the meta-analysis. No articles were
excluded from the entire review because of missing data. Data
quality was assured by comparing all studies to the Consolidated
Standards of Reporting Trials statement checklist (18).
Data analysis
All studies were reviewed against a qualitative analysis score,
and studies with complete data were quantitatively analyzed with
RevMan software (version 5.1.4) (19) with the outcome repre-
sented via forest plots (see figures). Results for the meta-analysis
could be obtained only when 2 studies were included that had
complete data for the specific outcome that was being assessed.
Two initial meta-analyses were completed by looking at whether
there was an effect on the efficacy of vitamins D2 and D3 in the
raising of serum 25(OH)D concentrations that was dependent on
the frequency of dosage [ie, daily administration and single or
infrequent bolus (either intramuscular or oral)]. The aim of the
main meta-analysis (irrespective of dosage frequency) was to
determine whether the change in serum 25(OH)D after inter-
vention was the same between vitamins D2 and D3 (which in-
dicated equal efficacy) or whether the change from baseline was
greater with vitamin D3.
Assessment of heterogeneity, sensitivity, and risk of bias
To account for the heterogeneity between included studies,
a random-effects model was used, in addition to the use of the
weighted mean difference. The I2 statistic was reported to in-
dicate the heterogeneity across the studies used for each meta-
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analysis. A result .75% was deemed likely to indicate a high
level of heterogeneity between studies, and 25% indicated
a low level of heterogeneity (20). Because of the practical dif-
ficulties of obtaining individual participant data and the small
number of studies available for review, a meta-regression was
not possible to further explore the cause of any possible het-
erogeneity. There were insufficient studies available to complete
an analysis of publication bias; however, a search of clinical
trials registries was completed to assess the number of studies
that declared a vitamin D intervention compared with studies
subsequently reported in the literature in an attempt to assess the
potential for publication bias. All included studies were quali-
tatively assessed for allocation, attrition, and reporting bias.
RESULTS
Search results
As per the Quality of Reporting ofMeta-analyses flow diagram
(Figure 1), 7 of 10 possible studies were included in the meta-
analysis, with one study that did not meet the criteria for in-
clusion in the meta-analysis because of a lack of random
assignment of participants; however, the study was still suitable
for qualitative review. Two studies had missing data or the au-
thors could not be contacted. A total of 3020 studies did not
meet the criteria for both quantitative and qualitative review
because of a number of reasons, such as an irrelevance to the
subject, a lack of random assignment of participants, a lack of
direct comparison between ergocalciferol and cholecalciferol, or
studies that were conducted in animals, cell models, or children.
Study characteristics
In the collective of 10 studies, there were 1016 participants
aged 18–97 y. The participant ratio of men to women was ;1:3,
with one study (16) that did not declare the sex of participants
(n = 95). The studies were conducted in the United States,
Canada, United Kingdom, Australia, Denmark, and Italy; all
studies were single-center studies. Seven studies were conducted
in healthy, free-living participants (4, 6, 7, 12, 13, 15, 17); one
study focused on elderly women who were residents of a nursing
home and were deficient in vitamin D (5), whereas another study
instead focused on hospital inpatients who had been diagnosed
with a hip fracture and were vitamin D deficient (16). The final
study recruited participants who were under the care of a rheu-
matology outpatient clinic (diagnosis unspecified) and were vi-
tamin D insufficient (14).
All intervention studies, except one study (14), declared that
the studies had a randomized, parallel design. Only 4 studies used
a control or placebo group to compare against intervention groups
(4, 6, 7, 13), and of those, only 3 studies implemented double
blinding of the intervention (4, 6, 7). Of the 6 studies that chose
not to compare intervention groups against a control group (5, 12,
14–17), 3 studies were double blind to the intervention (12, 15,
16). The remaining 3 studies used either a single-blinded (pre-
sumed that the participant was blinded to the intervention) (5, 17)
or an unblinded strategy (14).
The interventions used for all studies were vitamins D2 and D3
of varying dosages and treatment time periods. One study chose
to give a single bolus orally of 50,000 IU (13); one study chose
to administer one single large bolus of vitamin D2 or D3
(300,000 IU) and to also compare the route of administration (ie,
FIGURE 1. QUOROM statement flow diagram (29) indicating numbers of articles reviewed and later excluded or included for the systematic review and
meta-analysis. QUOROM, Quality of Reporting of Meta-analyses.
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intramuscular and oral) (5). Six studies preferred daily oral
supplementation strategies by using dosages between 1000 and
4000 IU (4, 6, 7, 12, 15, 16). One study chose a weekly in-
tervention of 50,000 IU (17), and another study chose a daily
compared with monthly intervention by using 1600 and 50,000
IU, respectively (15). The final study compared a single in-
tramuscular injection of 300,000 IU of vitamin D2 compared
with a single oral dose of 300,000 IU of vitamin D3 (14).
Treatment follow-up times varied from 28 d to 24 wk for the
bolus-intervention studies, whereas the daily and weekly study
designs had intervention periods that ranged from 14 d to 12 mo.
Compliance was reported to be .90% in 6 studies (5–7, 14,
15, 17) and invariably was verified via a pill count or stated by
the research team if doses were administered by or in the
presence of a clinician. For studies that involved bolus dosages,
compliance was assumed at 100% because of the study design
because it was presumed from the details of the study design
that a clinician was present to administer the dose or, at mini-
mum, observed the participant when the dose was consumed.
One study reported that 53% of participants completed the study
at a compliance rate 80% (16); 3 studies did not report the
monitoring of compliance to the intervention (4, 12, 13).
All studies, except 3 studies (5, 14, 16), stated that the vitamin D
content of intervention products was verified to ensure consistency.
In addition to the vitamin D supplementation, 3 studies also
supplemented with between 350 and 600 mg Ca/d (7, 12, 16). The
additional supplementation was either due to the calcium already
being present as part of the intervention product or as a deliberate
concomitant use of calcium as part of the study design. One study
conducted a 2-mo run-in diet before commencement of the in-
tervention period that contained 1000–1500mgCa/d, but it was not
clear whether this dietary program continued for the duration of the
vitamin D–supplementation period.
Methodologic quality
As a general overview, all studies included in the meta-analysis
showed a moderately clear methodology and subsequent
reporting of results (studies are described in Table 1). However,
across all studies, there were some notable omissions with re-
spect to the statistical analysis strategy, reasoning behind the
study design, and an overall general lack of attention to detail
that would make the dissemination of results much more fruitful
for all interested parties. The recruitment criterion for each study
was briefly described, and all studies stated that a random
assignment of participants had occurred (when it was part of
the study design); however, few studies detailed the actual
randomization strategy (ie, block randomization or computer-
generated code) (7, 12, 16). As previously described, all studies,
except one study, were of a randomized, parallel design. Four of
10 studies used a control group to compare against intervention
groups, and 6 studies of 10 were double blinded. Thus, only 3 of
10 possible studies included in the meta-analysis were ran-
domized, controlled, double-blind, parallel intervention studies,
which is the gold-standard design in nutrition research. There-
fore, because of the lack of specific information surrounding the
randomization and allocation of intervention to participants in
all studies, there was an unknown degree of selection, perfor-
mance, and detection bias. Concern was also raised regarding
stratification during the randomization process for sex. Three
studies had very high proportions of female participants, which
appeared to be unevenly distributed between intervention groups
(6, 7, 14). One study also had very mismatched participant
numbers when the 2 intervention groups of ergocalciferol (n =
50) and cholecalciferol (n = 19) were compared, which (in
combination with a lack of control group and an unblinded study
design) resulted in a tremendous weakening of its methodologic
quality and, thus, resulted in the study not being included in the
meta-analysis.
Attrition bias was difficult to qualify because of a lack of detail
given by all studies. Two studies made specific reference to
dropouts and sought to give some clarification about the reasons
for dropout or noncompliance (15, 16), whereas 3 studies
recorded dropout rates but gave no satisfactory detail as to the
reasons for dropout (6, 7, 17). The remaining studies either gave
no mention of dropouts (4, 12–14) or alternatively stated there
was full compliance to the study (5).
With respect to reporting bias, 8 of 10 studies reported all
outcomes as set out by their stated study aims and objectives (4–
7, 12, 13, 16, 17). However, in some cases, additional data that
detailed absolute changes in serum 25(OH)D concentrations,
alongside data already reported, would have proved helpful to
understand the outcomes and implications of these studies to
a greater degree. Two studies did not fully report on all outcomes
that were measured (14, 15), which, for both studies, centered on
markers of bone health that were not detailed, despite being stated
as measured in the study design and methodology.
A concern for all studies was the lack of consensus in the
analysis of serum 25(OH)D concentrations. Methods used for
analysis were reverse-phase HPLC, HPLC (UV detection), and
liquid chromatography–mass-spectrometry, of which CVs were
reported of ;9–12% for both intraassay and interassay (6, 7,
16). Radioimmunoassay was also used, with CVs of ;8%
intraassay and a 10% interassay reported (5). ELISA and chem-
iluminescence were implemented but lacked details on sensitivity
apart from one study that reported an intraassay CV of 2.6% for
the chemiluminescence assay (17). The competency of in-
dividuals who conducted the assays that measured serum markers
was invariably given little detail, which only added to concerns
for an additional potential bias when it was not known in full
whether all studies had serum analysis carried out by individuals
or contracted laboratories that followed rigorous procedures.
Furthermore, in one study (14), because of the large passage of
time (2 y) between the completion of the 2 intervention groups,
the serum analysis was completed by 2 different laboratories that
used 2 different techniques (chemiluminescence and ELISA),
which was a major contributory factor in the decision to remove
this study from the final meta-analysis.
The approach to statistical analysis in all studies generally
appeared sound, although in some areas, there was a lack of
specific details. For only one study, there was an estimated sample
size required to detect a treatment effect (16). Omissions of power
calculations caused great concern because of the relatively small
sizes of intervention groups for all the studies included in this review.
Meta-analysis
Eight intervention studies showed that, no matter the dosage,
the frequency or administration (oral compared with intramus-
cular) of cholecalciferol supplementation produced a significantly
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greater absolute increase from baseline of serum 25(OH)D
compared with ergocalciferol (4, 5, 12, 13, 14–17). Two studies (6,
7) showed that ergocalciferol and cholecalciferol were equally
efficacious.
Ten studies were available for the meta-analysis; however,
only 7 studies had sufficient and available data to be included in
the primary analysis by using the random effects model.
Overall, the analysis showed that the greater absolute change in
serum 25(OH)D from baseline favored the cholecalciferol in-
tervention, with a weighted mean difference of 15.23 (95% CI:
6.12, 24.34; Z = 3.28; P = 0.001; Figure 2). The heterogeneity
between studies was shown to be high (I2 = 81%), although this
unfortunately could not be investigated further by using meta-re-
gression because of the small number of studies available.
Separate analyses were performed to determine whether the
frequency of dosage had any effect on the favoring of either
ergocalciferol or cholecalciferol supplementation. Four studies
used either a single or multiple (weekly or monthly) bolus dosage
of 50,000–300,000 IU with anywhere from 4 wk to 1 y of follow-
up (5, 13, 15, 17). Three of these studies had data available that
showed that bolus doses favored cholecalciferol with a weighted
mean difference of 34.10 (95% CI: 16.38, 51.83; Z = 3.77; P =
0.0002; Figure 3). When we focused on studies that chose daily
supplementation (4, 6, 7, 12, 15, 16), the differentiation between
the 2 forms of vitamin D was not as clear cut. Although a clear
preference was shown for cholecalciferol supplementation
(1000–4000 IU/d), the result was nonsignificant with a weight
mean difference of 4.83 (95% CI: 20.98, 10.64; Z = 1.63; P =
0.10; Figure 4).
The heterogeneity for additional analyses was mixed; the bolus
analysis reported a high level of heterogeneity between studies
(I2 = 77%), but the daily supplementation analysis showed more
moderate levels of heterogeneity (I2 = 41%).
DISCUSSION
To our knowledge, our reported work is the first-ever sys-
tematic review and meta-analysis of the comparative effective-
ness of ergocalciferol compared with cholecalciferol in the
raising of serum 25(OH)D concentrations. We consider this study
to be a key investigation because of the widespread perception
that ergocalciferol and cholecalciferol are equally efficacious in
their respective abilities to raise serum 25(OH)D concentrations
(21). As shown in our meta-analysis results, after we reviewed
all known studies, there was a clear favoring of cholecalciferol
supplementation in the raising of serum 25(OH)D concentrations
compared with that of ergocalciferol supplementation (Figure 2).
We have also shown that, regardless of whether supplementation
with vitamin D was in small daily doses or in larger and more
infrequent bolus dosages, the favoring toward cholecalciferol
was still evident. The reasons why cholecalciferol is much more
proficient than ergocalciferol at raising serum 25(OH)D con-
centrations must be examined. Evidence has been accumulating
that specifically looks at the metabolism of vitamin D, especially
that focuses on the hydroxylation steps at the liver and kidney that
were required to convert the inert ergocalciferol and cholecal-
ciferol to the active calcitriol (1,25-dihydroxyvitamin D). As
described in the review of Houghton and Vieth (8) of the evidence
in 2006, it is clear that there are stark differences in the metabolic
fates of ergocalciferol and cholecalciferol that should not be ignored.
By centering on the differences in side chains between the 2 forms of
vitamin D [ergocalciferol has an additional methyl group on carbon
24 (22)], there have been reports that this difference directly affects
the rate of ergocalciferol conversion to serum 25(OH)D (9, 23, 24)
and also its affinity for vitamin D binding protein and VDR (8),
which are all critical steps involved in the activation of vitamin D.
Once the 2-step 25-hydroxylation process has been completed and
1,25-dihydroxyvitaminD has been formed, an additional step occurs
that involves 24-hydroxylation at the kidney to form 1,24,25(OH)3D
[1,24,25-trihydroxyvitamin D; 25(OH)D can also be converted to
24,25-dihydroxyvitamin D at this point] (8). As reported by Horst
et al (25), it is this 24-hydroxylation step that truly demarcates the
impact of ergocalciferol compared with that of cholecalciferol. This
differentiation between ergocalciferol and cholecalciferol is due to
the fact that once 1,24,25(OH)3D2 has been formed, ergocalciferol
has been deactivated and, therefore, is irretrievable (25). In contrast,
cholecalciferol [now 1,24,25(OH)3D3] retains its capacity to bind to
the VDR (8) and still requires an additional side-chain oxidation to
FIGURE 2. Random-effects meta-analysis comparing the effects of daily and bolus supplementation of D3 with that of D2 on net changes in serum 25(OH)D
concentrations. The forest plot indicates that the absolute change in 25(OH)D from baseline favored the D3 intervention. In the figure, “D25(OH)D” denotes
the change in serum 25(OH)D concentrations from baseline (net change), squares denote mean differences [with 95% CIs (lines)], and “Total” denotes the
cumulative n from all included studies. With the use of a random-effects model, overall, there was a significantly greater effect in the raising of serum 25
(OH)D concentrations over time for D3 supplementation than for D2 supplementation (mean difference: 15.23; 95% CI: 6.12, 24.34; P = 0.001). D2, vitamin
D2; D3, vitamin D3; IV, inverse variance; 25(OH)D, 25-hydroxyvitamin D.
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become deactivated (25). Thus, this additional step gives a vast
advantage and potential for cholecalciferol to remain biologically
active and, thus, maintain vitamin D status, which only strengthen
the hypothesis that cholecalciferol is the preferred substrate com-
pared with ergocalciferol.
This complication in the hydroxylation and deactivation
processes of ergocalciferol and cholecalciferol that could impact
efficacy is explored to some degree in a small number of the
clinical trials included in this review. Armas et al (13) and Heaney
et al (17) showed that, over a time course, cholecalciferol induced
a quicker response in the production of serum 25(OH)D that was
sustained for longer and at higher concentrations than did
ergocalciferol. In Heaney et al (17), weekly doses of 50,000 IU
(for 12 wk) induced AUC values for cholecalciferol that were
significantly higher than those for ergocalciferol; Heaney et al
(17) also noted that, once the doses of vitamin D were stopped at
week 12, there was evidence of far greater rates of degradation of
serum 25(OH)D2 (ergocalciferol) than serum 25(OH)D3 (cho-
lecalciferol) over a 6-wk time period. Armas et al (13) chose
a single bolus of 50,000 IU that again showed a significantly
greater AUC for cholecalciferol than for ergocalciferol, with
serum 25(OH)D2 concentrations that fell rapidly back to base-
line after only 14 d, whereas serum 25(OH)D3 concentrations
peaked at the same time point and had not returned to baseline at
the end of the 28-d intervention.
When the evidence from the studies that focused on vitamin D
metabolism at the cellular level is compared with the evidence
from clinical trials, it is clear that, overall, there was consistency
in the results that shows cholecalciferol appears to have ad-
vantageous biological qualities that allows it to sustain its sys-
temic influence for far longer and at far greater concentrations
than does ergocalciferol. However, not all the clinical trials agree
with this outcome, and 2 clinical trials showed no difference in
the efficacy of ergocalciferol compared with cholecalciferol (6,
7), which indicated the possibility that the not all possible in-
fluences on vitamin D metabolism have been accounted for in the
research completed to date.
The main limitation of this review was the small number of
studies available within the literature, which, in turn, limited, to
some degree, the ability to extrapolate the outcomes of this re-
view toward realistic public health recommendations when re-
ferring to ergocalciferol and cholecalciferol supplementation. In
addition, as described previously, the small number of studies
also limited, to some degree, the confidence in our knowledge of
the metabolism of vitamin D and whether all influences have been
examined and quantified.
The intervention strategy across all studies was diverse with
respect to the chosen dosage of vitamin D, the frequency of
supplementation, and the method of administration used (oral
compared with intramuscular), which inevitably contributed to
the high levels of heterogeneity (Figure 2). In addition, there were
recurring issues across all studies in terms of the depth and detail
of reporting. Many omissions were shown in the reporting of the
randomization strategy, power calculations, and subject com-
pliance. In scientific reporting, this lack of detail is unacceptable,
especially given the crucial role of such studies in establishing
key data within the vitamin D field. A lack of serious bias was
only assured because of the clear detail that referred to the
blinding of subjects and investigators and the overall attention to
detail when methodologies were reported.
It was also noted that all studies gave ergocalciferol and
cholecalciferol supplementation dosages far above the amount
FIGURE 3. Random-effects meta-analysis comparing the effects of bolus supplementation of D3 with that of D2 on net changes in serum 25(OH)D
concentrations. The forest plot indicates that the absolute change in 25(OH)D from baseline favored the D3 intervention when administered as a bolus dose. In
the figure, “D25(OH)D” denotes the change in serum 25(OH)D concentrations from baseline (net change), squares denote mean differences [with 95% CIs
(lines)], and “Total” denotes the cumulative n from all included studies. With the use of a random-effects model, overall, there was a significantly greater effect
in the raising of serum 25(OH)D concentrations over time for D3 supplementation as a bolus dosage (single and multiple bolus) than for D2 supplementation
(mean difference: 34.10; 95% CI: 16.38, 51.83; P = 0.0002). D2, vitamin D2; D3, vitamin D3; IV, inverse variance; 25(OH)D, 25-hydroxyvitamin D.
FIGURE 4. Random-effects meta-analysis comparing the effects of daily supplementation of D3 with that of D2 on net changes in serum 25(OH)D
concentrations. The forest plot indicates that the absolute change in 25(OH)D from baseline favored the D3 intervention as a daily supplement. “D25(OH)D”
denotes the change in serum 25(OH)D concentrations from baseline (net change), squares denote mean differences [with 95% CIs (lines)], and “Total” denotes
the cumulative n from all included studies. With the use of a random-effects model, overall, there was no significant difference between D2 and D3
interventions in the raising of serum 25(OH)D concentrations when taken as a daily supplement (mean difference: 4.83; 95% CI: 20.98, 10.64; P =
0.10). D2, vitamin D2; D3, vitamin D3; IV, inverse variance; 25(OH)D, 25-hydroxyvitamin D.
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currently recommended [Recommended Dietary Allowance of
600 IU for males and females aged 1–70 y (26)]. Although this
strategy can be a useful methodology to force a physiologic
change (and, thus, to possibly piece together a mechanism of
action), these studies offered little information for lower doses,
which are more realistic in terms of what individuals are likely to
be able to consume within their daily diet and gain from sunlight
exposure and the concentrations of ergocalciferol and chole-
calciferol available in commercial supplements. Thus, in com-
bination with the small and underpowered study populations (n =
19–89) and lack of data in lower doses, there is a clear need for
additional research to ascertain whether the results obtained
within the studies included in this review translate across the
entire dose-response curve.
In conclusion, our results suggest a favoring toward chole-
calciferol rather than ergocalciferol supplementation with respect
to the more effective improvement of vitamin D status. When the
frequency of dosage administration was compared, there was
a significant response for vitamin D3 when given as a bolus dose
(P = 0.0002) compared with administration of vitamin D2, but
the effect was lost with daily supplementation. Far larger,
more robust trials are now required that not only monitor serum
25(OH)D concentrations but also explore much further the po-
tential mechanism behind this apparent discrepancy in effec-
tiveness between the 2 forms of vitamin D available. This
mechanistic approach should encompass the obvious need for
a description of genetic polymorphisms linked to vitamin D
metabolism and, also, the critical enzymes involved in the
hydroxylation process. These studies would provide an ideal
opportunity to identify the levels of enzymatic activity (micro-
somal cytochrome P450 2R1, mitochondrial cytochrome P450
27A1, and cytochrome P450 27B1) and the spectrum of vitamin
D metabolites that are produced as part of the hydroxylation
process that would be able to account for the deactivation pro-
cess of ergocalciferol and cholecalciferol that appears to be the
central cause for the discrepancy between efficacies at this point
in time.
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